R&D tax credit
This article was originally published in The Gray Sheet
Executive Summary
Legislation (HR 835) introduced Feb. 24 by Reps. Nancy Johnson (R-Conn.) and Robert Matsui (D-Calif.) would amend the Internal Revenue Code of 1986 to permanently extend the research and development tax credit, which is slated to expire June 30. The bill currently has 98 co-sponsors
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.